Results 51 to 60 of about 4,708 (131)

Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT To achieve hepatitis B virus (HBV) elimination in Australia, a shift from hospital to community‐based care is needed. This study aimed to describe the prevalence of chronic HBV and uptake of the cascade of care in primary care patients. This prospective cohort study was conducted in 76 urban and regional primary care clinics across Victoria ...
Dina Moussa, Jack Wallace, Jacqui Richmond, Joseph S. Doyle, Long Nguyen, Douglas Boyle, Mark A. Stoové, Jason Asselin, Victoria Polkinghorne, Marvad Ahad, Susanne Glasgow, Kate New, Lena Sanci, Matt Penn, John Furler, Alexander Thompson, Margaret Hellard, Jess Howell   +17 more
wiley   +1 more source

Hypovitaminosis D‐Induced Secondary Hyperparathyroidism With Concomitant Femoral Fracture in a Chronic Hepatitis B Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Vitamin D deficiency and secondary hyperparathyroidism (SHPT) are preventable causes of metabolic bone disease, yet they may remain clinically silent until catastrophic skeletal events occur. Chronic hepatitis B virus (HBV) infection has been increasingly linked to disordered bone and mineral metabolism, even in the absence of cirrhosis.
Walter Appati, Kojo Awotwi Hutton‐Mensah, Landrop Aidoo, Naa Akweley Suma Otchwemah   +3 more
wiley   +1 more source

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

BMC Infectious Diseases, 2019
Background Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function.
Bernard Surial, Matthias Cavassini, Alexandra Calmy, Jan Fehr, Marcel Stöckle, Enos Bernasconi, Bianca Roth, Christoph A. Fux, Helen Kovari, Hansjakob Furrer, Andri Rauch, Gilles Wandeler, the Swiss HIV Cohort Study   +12 more
doaj   +1 more source

The Caribbean, Central and South America Network for HIV Epidemiology: 20 Years of HIV Research in the Region

Journal of the International AIDS Society, Volume 29, Issue S3, July 2026.
ABSTRACT Introduction Latin America is a key region in advancing efforts to end the HIV epidemic globally. Despite breakthroughs in HIV treatment and prevention in the last 20 years, as well as region‐wide improvements in health infrastructure and policies, there has been a 13% increase in new acquisitions in Latin America from 2010 to 2024.
Jessica L. Castilho, Stephany N. Duda, Bryan E. Shepherd, Timothy R. Sterling, Anna K. Person, Peter F. Rebeiro, William C. Wester, John R. Koethe, Jesse Carlson, Rachael A. Pellegrino, Karu Jayathilake, Fernanda Maruri, Hilary Vansell Riley, Amanda Garcia De Matos Amaral, Marina Cruvinel Figueiredo, Paridhi Ranadive, Megan Turner, Gustavo Amorim, Vickie Myers, Heather Burgess, Shengxin Tu, Liping Du, Danni Shi, Zhouhui Liang, Kaixing Liu, Chao Yan, Beatriz Grinsztejn, Valdilea G. Veloso, Paula M. Luz, Sandra Wagner Cardoso, Ruth Friedman, Ronaldo I. Moreira, Monica Derrico Pedrosa, Hugo Perazzo, Rodrigo Moreira, Maria Pia Diniz Ribeiro, Mario Sergio Pereira, Emilia Moreira Jalil, Thiago Silva Torres, Carolina Coutinho, Mayara Secco Torres Silva, Flaviana Pavan Victoriano, Jorge Pinto, Flavia Ferreira, Marcelle Maia, Victoria Bocardi, Julia Caporali, Flavia Fonseca, Mateus Westin, Regina Célia de Menezes Succi, Daisy Maria Machado, Aida de Fátima Barbosa Gouvêa, Fabiana Bononi do Carmo, Claudia P. Cortes, Maria Fernanda Rodriguez, Gabriel Castillo‐Rozas, Fabio Paredes, Georgina Estadella, Jean William Pape, Vanessa Rouzier, Adias Marcelin, Jodany Bernadin, Stanley Cadet, Marco Tulio Luque, Diana Varela, Magda Chavez, Ada Mailhot, Eduardo Gotuzzo, Fernando Mejia, Gabriela Carriquiry, Claudia Nuñez Mochizaki, Brenda Crabtree Ramirez, Juan Sierra Madero, Yanink Caro Vega, Álvaro López Iñiguez, Ana Fernanda Ramos Menchelli, Paola Alarcón Murra, Geovanna Coello, Guadalupe Muñuzuri Nájera, Rodrigo Ville Benavides, Jessica Mejía, Távata Bejarano, Nancy Sierra, Valeria Fink, Florencia Cahn, Ines Aristegui, Maria Ines Figueroa, Nicolas Doudtchitzky, Javier Mariani, Mariela Ceschel, Gissella Mernies, Agustin Nava, Carina Cesar, Pedro Cahn, Caribbean, Central and South America network for HIV Epidemiology (CCASAnet) of the International epidemiology Databases to Evaluate AIDS (IeDEA)   +95 more
wiley   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, Volume 56, Issue 7, Page 1140-1151, July 2026.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, Volume 27, Issue 7, Page 1189-1195, July 2026.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source

Beyond Viral Control: Tenofovir's Hidden Impact on Blood–Brain Barrier Endothelial Cells

Microcirculation, Volume 33, Issue 5, July 2026.
ABSTRACT The blood–brain barrier (BBB) is a dynamic endothelial interface that protects the brain from harmful agents while regulating molecular exchange. Human immunodeficiency virus (HIV) compromises BBB integrity, promoting neurological damage.
Saarah Behardien, Khayelihle Brian Makhathini, Chontrelle Willemse, David Fisher   +3 more
wiley   +1 more source

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy

Drug Design, Development and Therapy, 2017
Eiichi Ogawa,1 Norihiro Furusyo,1 Mindie H Nguyen2 1Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto,
Ogawa E, Furusyo N, Nguyen MH
doaj